Citation map · Study

SZodixStudyAcademic Library

Shelves Open access

Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated

Performance-Based Risk-Sharing Arrangements—Good Practices for Design, Implementation, and Evaluation: Report of the ISPOR Good Practices for Performance-Based Risk-Sharing Arrangements Task Force

2 references·16 citing·36 second hop

FromToDepth

this work references cited by second hop

References

2003Principles of Good Practice for Decision Analytic Modeling in Health-Care Evaluation: Report of the ISPOR Task Force on Good Research Practices—Modeling Studies1,170 cited
2005Good Research Practices for Cost-Effectiveness Analysis Alongside Clinical Trials: The ISPOR RCT-CEA Task Force Report721 cited

Cited by

2020Value of Information Analysis for Research Decisions—An Introduction: Report 1 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force204 cited
2017How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries203 cited
2014Dealing with uncertainty and high prices of new medicines: A comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden156 cited
2018Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare124 cited
2013Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries122 cited
2017The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications122 cited
2014Italian risk-sharing agreements on drugs: are they worthwhile?114 cited
2020Managed Entry Agreements: Policy Analysis From the European Perspective113 cited
2022The ecosystem of health decision making: from fragmentation to synergy109 cited
2017Gene therapy: evidence, value and affordability in the US health care system

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

105 cited

2019Analytic Considerations in Applying a General Economic Evaluation Reference Case to Gene Therapy92 cited

2015Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review92 cited

2017Performance-Based Risk-Sharing Arrangements: An Updated International Review91 cited

2018Managed Entry Agreements for Pharmaceuticals in the Context of Adaptive Pathways in Europe71 cited

2020HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies71 cited

2017Value quantification capabilities in industrial markets67 cited